Foxx Development 2/14/2025 Earnings Report

Foxx Development EPS Results

• Actual EPS: $0.20
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Foxx Development Revenue Results

• Actual Revenue: $17.48 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Foxx Development Announcement Details

• Date: 2/14/2025
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Foxx Development (NASDAQ:FOXX), Inc. (NASDAQ: FOXX) operates as a contract manufacturer specializing in the design, assembly and distribution of medical devices and components. The company’s core business centers on phlebotomy and blood collection products, serving clinical laboratories, hospitals and diagnostic testing facilities. Its product portfolio includes evacuated blood collection tubes, safety-engineered winged blood collection sets, syringes and ancillary devices used in specimen collection and handling.

Founded in North Carolina, Foxx Development maintains a manufacturing and distribution campus in Apex, where it integrates engineering, quality control and regulatory compliance under one roof. The company leverages clean-room production and ISO-certified processes to meet stringent U.S. Food and Drug Administration (FDA) requirements as well as international quality standards. Through both private-label and contract manufacturing agreements, Foxx supports original equipment manufacturers (OEMs) and global distributors seeking to outsource production of single-use medical products.

Foxx Development serves customers across North America and exports to select international markets, aligning its operations with the needs of leading diagnostics companies. By offering end-to-end services—from product design and prototyping to large-scale production and logistics—the firm enables customers to accelerate time-to-market while maintaining focus on core research, development and marketing activities.

Under the leadership of its senior management team, Foxx Development places strong emphasis on innovation, quality assurance and regulatory adherence. The company continues to invest in process optimization and facility enhancements aimed at expanding capacity and supporting evolving customer requirements in the clinical diagnostics sector.